Trial Profile
Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Liraglutide (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms SCALE™ Insulin
- Sponsors Novo Nordisk
- 05 Mar 2020 Results published in the Diabetes Care
- 08 Oct 2018 Status changed from active, no longer recruiting to completed.
- 05 Mar 2018 Planned primary completion date changed from 1 Aug 2018 to 28 Aug 2018.